Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Protocol for Radiofrequency Ablation of Pulmonary Neoplasms

This study has been terminated.
Sponsor:
Information provided by:
Oncology Specialties, Alabama
ClinicalTrials.gov Identifier:
NCT00232128
First received: October 3, 2005
Last updated: January 11, 2007
Last verified: May 2006
  Purpose

This research trial involves the development of a new treatment for lung tumors. It is for patients whose tumor cannot be surgically removed, have refused surgery, or the tumor has not responded well to other forms of treatment. This treatment uses a needle probe to deliver energy into the lung tumor. This probe is placed utilizing a CT scan image. The energy heats the tumor causing tumor cell death.


Condition Intervention
Pulmonary Neoplasms
Procedure: Radiofrequency Ablation of pulmonary neoplasms

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Protocol for Radiofrequency Ablation of Pulmonary Neoplasms

Resource links provided by NLM:


Further study details as provided by Oncology Specialties, Alabama:

Study Start Date: June 2003
  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: The patients enrolled in this study should be judged to have sufficient survival to benefit from control of local disease and include at least one of the following:

  1. unresectable primary or metastatic lung tumors
  2. may benefit from multiple modalities of therapy
  3. chemotherapeutic or radiation oncologic options have been exhausted

Exclusion Criteria:

1. co-existing morbidities that preclude the use of surgery

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00232128

Locations
United States, Alabama
Comprehensive Cancer Institute
Huntsville, Alabama, United States, 35801
Sponsors and Collaborators
Oncology Specialties, Alabama
Investigators
Principal Investigator: Marshall T. Schreeder, M.D. Comprehensive Cancer Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00232128     History of Changes
Other Study ID Numbers: CCI LUN 02
Study First Received: October 3, 2005
Last Updated: January 11, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Lung Neoplasms
Neoplasms
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms

ClinicalTrials.gov processed this record on November 20, 2014